Effects of plasma glucose levels on regional cerebral 18F-fluorodeoxyglucose uptake: Implications for dementia evaluation with brain PET imaging.
FDG uptake in hyperglycemia
Misdiagnosis of dementia
Nondiabetic patients
Regional cerebral FDG uptake
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
08
01
2019
revised:
22
01
2019
accepted:
24
01
2019
pubmed:
21
2
2019
medline:
11
7
2019
entrez:
21
2
2019
Statut:
ppublish
Résumé
Hyperglycemia affects FDG uptake in the brain, potentially emulating Alzheimer's disease in normal individuals. This study investigates global and regional cerebral FDG uptake as a function of plasma glucose in a cohort of patients. 120 consecutive male patients with FDG PET/CT for initial oncologic staging (July-Dec 2015) were reviewed. Patients with dementia, cerebrovascular accident, structural brain lesion, prior oncology treatment or high metabolic tumor burden (recently shown affecting brain FDG uptake) were excluded. 53 (24 nondiabetic) eligible patients (age 65.7 ± 2.8 mean ± SE) were analyzed with parametric computer software, MIMneuro™. Regional Z-scores were evaluated as a function of plasma glucose and age using multi variable linear mixed effects models with false discovery analysis adjusting for multiple comparisons. If the regression slope was significantly (p < 0.05) different than zero, hyperglycemia effect was present. There was a negative inverse relationship (p < 0.001) between global brain FDG uptake and hyperglycemia. No regional hyperglycemia effect on uptake were present when subjects were normalized using pons or cerebellum. However, regional hyperglycemia effects were seen (p < 0.047-0.001) when normalizing by the whole brain. No obvious pattern was seen in the regions affected. Age had a significant effect using whole brain normalization (p < 0.04-0.01). Cortical variation in FDG uptake were identified when subjects were hyperglycemic. However, these variations didn't fit a particular pattern of dementia and the severity of the affect is not likely to alter clinical interpretation.
Identifiants
pubmed: 30784923
pii: S0753-3322(19)30129-5
doi: 10.1016/j.biopha.2019.108628
pmc: PMC6714976
mid: NIHMS1030686
pii:
doi:
Substances chimiques
Blood Glucose
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108628Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM103542
Pays : United States
Organisme : NCRR NIH HHS
ID : P20 RR024485
Pays : United States
Organisme : NINDS NIH HHS
ID : P50 NS091856
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier Masson SAS.
Références
Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E141-5
pubmed: 20009031
Metabolism. 2016 Feb;65(2):124-39
pubmed: 26773935
J Cereb Blood Flow Metab. 2015 Aug;35(8):1380-5
pubmed: 26058692
Ann Nucl Med. 2008 Apr;22(3):191-200
pubmed: 18498034
J Neurochem. 1983 Jan;40(1):160-7
pubmed: 6848656
Neuroimaging Clin N Am. 2005 Nov;15(4):837-46, x
pubmed: 16443494
Ann Nucl Med. 2010 Jul;24(6):501-5
pubmed: 20237872
Semin Nucl Med. 2003 Jan;33(1):77-85
pubmed: 12605358
J Cereb Blood Flow Metab. 1989 Jun;9(3):304-14
pubmed: 2715202
AJR Am J Roentgenol. 2015 Jan;204(1):W76-85
pubmed: 25539279
Radiographics. 2014 May-Jun;34(3):684-701
pubmed: 24819789
J Cereb Blood Flow Metab. 1990 Nov;10(6):765-73
pubmed: 2211874
Biomed Pharmacother. 2017 Apr;88:1038-1045
pubmed: 28192877
J Nucl Med. 2015 Feb;56(2):229-33
pubmed: 25572094
Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):2103-10
pubmed: 19838705
J Cereb Blood Flow Metab. 1981;1(1):7-36
pubmed: 7035471
Radiology. 2018 Jun;287(3):993-1002
pubmed: 29558296
J Nucl Med. 2007 Jul;48(7):1129-34
pubmed: 17574982
J Cereb Blood Flow Metab. 1990 Jul;10(4):499-509
pubmed: 2347881
Eur Radiol. 2015 Sep;25(9):2701-8
pubmed: 25899414